Project Grant R41AI186686
Award Date
7/10/24
Completion Date
6/30/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Ubiquitx Inc. (LRA7LGJCZP15)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10024, USA
Similar Awards
This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...
This Project Grant award of $910,905 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by the Scripps Research Institute to develop an HIV vaccine using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,269,762 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University. The grant will fund the development of a microfluidic platform called SECRE (Secretion-Enabled Cell Ranking and Enrichment) to enable high-performance sorting of immune cells based on their secretion patterns. This technology will be leveraged to conduct genome-wide CRISPR activation and/or...
This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
This Project Grant award of $392,634, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Emmune Inc. to conduct pre-clinical IND-enabling studies for ECD4-IG, a long-acting recombinant protein therapeutic for HIV. The award will support in vitro assays, a pre-IND meeting with the FDA, and a definitive GLP toxicology study in macaques to assess safety and toxicity, in preparation for a Phase 1...
This Project Grant award, valued at $807,664.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports the development and high-content screening of a library of over 50,000 bifunctional interferon chimeras by Heligenics, Inc., a small business located in Las Vegas, Nevada. The goal is to identify and validate more potent interferon protein variants for potential clinical...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an innovative proteoliposome-based delivery system for therapeutic and bioactive cargo. The $213,284 award will fund research to repurpose viral fusion machinery, including proteins from influenza, Nipah virus, and SARS-CoV-2, to improve cellular uptake and targeted delivery of user-defined cargo. The...
This federal Project Grant award of $658,657, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the biophysical and functional coupling of protein condensates to ordered lipid domains in T-cells. The principal investigator from the University of Virginia will lead this 5-year research project, collaborating with a subrecipient, The Hospital for Sick Children, to...